FDA approves GSK’s drug Horizant for a new cure

Horizant, a medication which was already approved for treatment of restless legs syndrome (RLS) is recently been approved by the FDA (Food and Drug Administration) to be used as a therapeutic remedial approach for curing the nerve pain associated with shingles. The drug is the baby of XenoPort Inc and GlaxoSmithKline Plc drug manufacturers, but currently the two pharma companies, who are partners, are undergoing a legal fight as it has been alleged by XenoPort that GSK has breached with the contract. The approval of the drug for treatment of post-herpetic neuralgia (PHN) in young individuals is proved to of great significance as around 1 million individuals in the U.S have been found to get afflicted from shingles every year. Of the total individuals affected from this detrimental condition, approximately 10 % of the patients were found to develop this detrimental health condition called PHN. This catastrophic condition results from the curing of the infection caused by the outbreak of the virus herpes zoster, which is known commonly as shingles. The controlled clinical trial study of the drug Horizant to find the effectiveness and potency of the drug for healing of post-herpetic neuralgia was carried out for a period of 12 weeks. The common but mild side effects that were observed in PHN suffering patients, who underwent the treatment, include dizziness and drowsiness. Michael Yee, RBC Capital analyst said that despite the fact that XenoPort shares have seen a downfall following the dispute of contract with GSK, it is reported that XenoPort will be getting a high point payment of around $10 million from its partner once, the first set of sales of the medication is done. Acedrugstore 3rd Street, Bakersfield, CA, USA 93311 16471051516 http://www.acedrugstore.com/ http://www.acedrugstore.com/kamagra-jelly.html

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.